Thirty one patients with giant cell arteritis (GCA) receiving standardised prednisolone treatment were followed up for one year with analyses of plasma viscosity, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and fibrinogen concentration. On the day of diagnosis all patients had an increased plasma viscosity and ESR, whereas the concentration of CRP was normal in three patients and fibrinogen concentration 
Giant cell arteritis (GCA) is a clinically heterogeneous syndrome of unknown aetiology and associated with a considerable systemic inflammatory reaction. ' 2 The erythrocyte sedimentation rate (ESR) has long been generally recommended in the clinical monitoring of this disease, 7 even in comparison with other acute phase reactants such as C reactive protein (CRP).7 Although the ESR is usually increased in patients with GCA before treatment,7 normal values have been reported in 25% of patients. 8 Of particular concern is the occurrence of normal ESR values even in fulminant cases of GCA.2 9 Another problem is the failure of the ESR to predict relapses.9 0 So far, no laboratory test has been found unfailingly to predict the severity of the disease2 and the judgement therefore still has to be based on clinical findings.2 10 Changes in blood rheology could be expected in GCA due to the increased protein concentrations-for example, of fibrinogen. " Four previous studies have shown increased plasma viscosity in patients with GCA,'12-whereas no changes in whole blood viscosity or in the rheological properties of erythrocytes have been found. 15 Plasma viscosity has not been shown to be superior to the ESR in the monitoring of GCA3 5 but its value has not yet been tested in a longitudinal study ofpatients receiving a uniform therapeutic regimen.
The aim of this study was to evaluate prospectively the clinical significance of plasma viscosity compared with acute phase reactants in the clinical monitoring of GCA. Thirty one patients with GCA were followed from the early phase and during the first year of standard prednisolone treatment.
Patients and methods

PATIENTS
Thirty one consecutive patients with the diagnosis of GCA (seven men, 24 women) were included. The 20 The normal ranges at our clinical laboratory were 2-4 g/l for fibrinogen concentration, 7-17 g/l for IgG, 0-4-1-8 g/l for haptoglobin, and 0-10 tg/l for CRP.
STATISTICAL METHODS
The t test was used for comparisons between groups. Pearson correlation coefficients were used to measure the degree of association. The probability of flare up within the first year and after the first month of high dose glucocorticoid treatment was estimated by logistic regression analysis as a function of the ESR, plasma viscosity, or both. The corresponding curve equals the derivative of the receiver operating characteristic curve." To obtain these curves, the probability of a flare up within the first year of treatment was estimated without consideration of the ESR or plasma viscosity. The hazard function was approximated by a piecewise constant function. The expected proportions of patients with flare up when increasing the glucocorticoid dose at different levels of plasma viscosity, ESR, or these tests combined were calculated from these data.
Results
Eight of the 31 patients had GCA as proved by taking a biopsy sample (table 1) . No significant differences were observed with respect to plasma fibrinogen concentration (r=0-6; p<005), haptoglobin (r=0 5; p<0 05), and IgG (r=0 6; p<0 01). C reactive protein correlated with fibrinogen concentration (r=0-7; p<001) but not with ESR (r=0-4; NS). The erythrocyte sedimentation rate correlated with fibrinogen concentration (r=0-7; p<0 001) and with IgG (r=0-5; p<0 05). The duration of symptoms showed no significant correlation with any of the laboratory variables except for a negative correlation with CRP (p<0 05) (table 2) . Multiple regression with plasma viscosity as the dependent variable showed that IgG was the strongest independent variable, followed by the ESR. With two independent variables, fibrinogen concentration and erythrocyte sedimentation rate, the regression was significant (r=0-6; p<0 05) but neither of the two independent variables reached significant levels, probably because they are strongly interrelated. Correlation analysis for plasma viscosity with other laboratory variables while controlling for fibrinogen concentration showed that only IgG correlated significantly (r=0-6; p<005). Controlling for IgG showed significant correlation only between haptoglobin and plasma viscosity (r=0-6; p<0 05). After four days of treatment, significantly lower values of laboratory tests were found for all variables except ESR (figs 2 and 3). The mean (SD) value of plasma viscosity at day zero was 2-13 (0 225) mPa s and at day four 1-92 (0-160) mPa s (p<001). The mean (SD) ESR at day zero was 71 (28-1) mm/hour and at day four 54 (28-1) mm/hour (NS). C reactive protein at day zero was 53 (34-9) [ig/l and at day four 24 (20:4) mgIl (p<005) and fibrinogen concentration at day zero was 6-1 (1-34) g/l and at day four (1-01) gil (p<001). After 10 days of treatment we observed an upwards drift in plasma viscosity and ESR (fig 1) but there was no significant difference between days four and ten. This was not found for fibrinogen concentration or CRP. Clinically, however, there was no sign of flare ups at day ten.
C reactive protein tended to decrease faster than any other laboratory variable and all patients had normal values after three weeks ( fig  3) . Plasma viscosity showed significant changes earlier than the ESR (at day four) but the ESR decreased faster than the plasma viscosity as the treatment progressed (fig 2) . After 10 (fig 4) . Using the hazard function, the probability of flare up within the first year and after the first month of high dose glucocorticoid treatment was determined to be 0 50. The use of different levels of plasma viscosity, ESR, or the two tests combined to lower the proportion of patients developing a flare up by increasing the glucocorticoid dose was exemplified by the following estimates. The calculations were based on the successful treatment of 60, 50, and 40% of patients, corresponding to centiles 40, 50, and 60 respectively (fig 4) . Using the ESR to make the decision to increase the glucocorticoid dose, the proportion of patients with a flare up 16 20 24 28 during the first year of treatment would be reduced to 8% at a ESR of 12 mm/hour, 10% at an ESR of 14 
